An Integrated Development Plan in Rare & Orphan Medicinal Products – Accelerating Time to Approval and Strengthening Asset Value, Upcoming Webinar Hosted by Xtalks

Share Article

In this free webinar, attendees will learn about an advanced diagnostic tool that can support a proprietary evidence-based methodology for benchmarking your rare asset development program against best-in-class industry practices, as well as de-risking and enhancing value at each step of the product development journey.

Xtalks Life Science Webinars

The global pandemic has taken a heavy toll on the rare and orphan disease community and on drug development. Novel and integrated approaches linking Clinical, Regulatory, RWE and Commercialization, including early engagement of key stakeholders, are required to accelerate these products to market and de-risk the development of critical patient therapies.

To help innovative companies determine and execute the best path forward, our asset development experts from Syneos One® have developed ADAPT (Accelerate timelines, Drive evidence generation, Anticipate risks, Partner with stakeholders, be Transparent) an evidence-based diagnostic tool that optimizes clinical and regulatory strategy in order to accelerate products to market and build strong value propositions for market access and adoption.

Built from a robust evaluation of over 200 orphan assets launched since 2016 with 436 orphan drug designations granted in 40 therapeutic classes, ADAPT from Syneos One creates best-practice benchmarks specific to each customer’sbusiness needs, to maximize value for all stakeholders along the product development journey. The speakers will share how Syneos One asset strategists can use these findings, combined with the breadth of capabilities, depth of therapeutic expertise and integrated perspective at Syneos Health to build a comprehensive and informed strategy and roadmap to ensure asset success.

Join Maryna Kolochavina, PharmD, PMP, Executive Director, Syneos One, Rare Diseases and James Featherstone, Global Executive Vice President and Head of Syneos One in a live webinar on Friday, September 4, 2020 at 10am EDT (3pm BST/UK).

For more information or to register for this event, visit An Integrated Development Plan in Rare & Orphan Medicinal Products – Accelerating Time to Approval and Strengthening Asset Value.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sydney Perelmutter
Xtalks
+1 (416) 977-6555 x 352
Email >
Visit website